By Patrick Wingrove LONDON, Oct 15 (Reuters) - AstraZeneca has teamed up with artificial intelligence biotech company insitro ...

AstraZeneca is paying insitro $40 million upfront to find novel drug targets for liver and heart diseases using artificial ...

SOUTH SAN FRANCISCO, Calif., October 15, 2026--insitro, an AI company unlocking causal human biology to systematically generate high-value therapeutics to treat grievous illness, today announced a ...

On Monday, AstraZeneca Plc AZN shared detailed results from the HICKORY Phase 3 trial of efzimfotase alfa (ALXN1850) for ...

Astrazeneca (NYSE:AZN) presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for ...

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant ...

Summit shares surged in after-hours trading following the news of AstraZeneca’s investment, as the two companies plan to ramp up their collaboration on developing cancer treatments.

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was "rapidly transferring manufacturing" across the Atlantic. "This country [the U.S.] ...

AstraZeneca PLC boasts strong 2024 results with $54B revenue and 14 blockbuster drugs, driven by robust growth in oncology and rare disease franchises. Key products like Farxiga, Tagrisso, and ...

AstraZeneca is investing $2 billion in Miami-based Summit Therapeutics as the pharmaceutical giant deepens its relationship ...

The investment is expected to increase the pharma giant's workforce in Massachusetts to 3,000 employees within a few years.

Sept 28 (Reuters) - Summit Therapeutics said on Monday that British drugmaker AstraZeneca would invest $2 billion in the company and collaborate on a series of studies testing their cancer treatments ...